COMP <GO>
SGRY vs MRK // FORWARD P/E MULTIPLE
Surgery Partners Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: SGRY 7
— MRK 8
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $23.21 (0.00%) • MKT CAP: $3.04B
forward-pe
22.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGRY VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SGRY | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 20.70% | -10.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.7x | 15.3x | -5.60 | SGRY | /valuation <GO> |
| Free Cash Flow Yield | 6.44% | 3.42% | +3.02 | SGRY | /fcf-yield <GO> |
| Operating Margin | 45.80% | 34.30% | +11.50 | SGRY | /operating-margins <GO> |
| Net Profit Margin | -9.20% | 28.10% | -37.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 6.60% | 1.30% | +5.30 | SGRY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.67 | 5.19 | -4.52 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | SGRY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 86.2 | 56.9 | +29.30 | SGRY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.92 | +0.07 | SGRY | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 22.0x | 18.4x | +3.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.04B | $361.02B | -$357.98B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SGRY REV | MRK REV | SGRY GROSS % | MRK GROSS % | SGRY FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | $195.6M | $12.36B |
| FY 2024 | $0 | $64.17B | — | 76.3% | $209.7M | $18.10B |
| FY 2023 | $0 | $60.12B | — | 44.0% | $293.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGRY // BETA 0.99
MRK // BETA 0.92